Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

Daxa M. Patel; Paul M. Foreman; L. Burt Nabors; Kristen O. Riley; G. Yancey Gillespie; James M. Markert

doi:10.1089/humc.2016.031

Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

Human Gene Therapy Clinical Development ◽

10.1089/humc.2016.031 ◽

2016 ◽

Vol 27 (2) ◽

pp. 69-78 ◽

Cited By ~ 39

Author(s):

Daxa M. Patel ◽

Paul M. Foreman ◽

L. Burt Nabors ◽

Kristen O. Riley ◽

G. Yancey Gillespie ◽

...

Keyword(s):

Clinical Trial ◽

Glioblastoma Multiforme ◽

Phase I ◽

Anaplastic Astrocytoma ◽

Genetically Engineered ◽

Phase I Clinical Trial ◽

Hsv 1

Download Full-text

Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

Human Gene Therapy Clinical Development ◽

10.1089/hum.2016.031 ◽

2016 ◽

Cited By ~ 2

Author(s):

Daxa Patel ◽

Paul Foreman ◽

Burt Nabors ◽

Kristen Riley ◽

Yancey Gillespie ◽

...

Keyword(s):

Clinical Trial ◽

Glioblastoma Multiforme ◽

Phase I ◽

Anaplastic Astrocytoma ◽

Genetically Engineered ◽

Phase I Clinical Trial ◽

Hsv 1

Download Full-text

The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas

Frontiers in Surgery ◽

10.3389/fsurg.2020.00059 ◽

2020 ◽

Vol 7 ◽

Cited By ~ 1

Author(s):

M. R. Chambers ◽

R. Timothy Bentley ◽

David K. Crossman ◽

Jeremy B. Foote ◽

Jey W. Koehler ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

One Health ◽

Checkpoint Inhibitor ◽

Genetically Engineered ◽

Phase I Clinical Trial ◽

High Grade ◽

High Grade Gliomas ◽

The One ◽

Hsv 1

Download Full-text

Phase I clinical trial of intrahepatic arterial infusion of a HSV-1 replication-conditional mutant (rRRp450)

Journal of Vascular and Interventional Radiology ◽

10.1016/j.jvir.2013.12.108 ◽

2014 ◽

Vol 25 (3) ◽

pp. S45

Author(s):

S. Ganguli ◽

R. Oklu ◽

J.W. Clark ◽

E.L. Kwak ◽

S.P. Kalva ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Phase I Clinical Trial ◽

Arterial Infusion ◽

Conditional Mutant ◽

Hsv 1

Download Full-text

Phase I Clinical Trial of a Genetically Modified and Oncolytic Vaccinia Virus GL-ONC1 in patients with peritoneal carcinomatosis

Zeitschrift für Gastroenterologie ◽

10.1055/s-0032-1324086 ◽

2012 ◽

Vol 50 (08) ◽

Author(s):

UM Lauer ◽

M Zimmermann ◽

U Koppenhöfer ◽

M Bitzer ◽

NP Malek ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Vaccinia Virus ◽

Peritoneal Carcinomatosis ◽

Genetically Modified ◽

Phase I Clinical Trial

Download Full-text

SAFETY OF A NEW CUBAN PNEUMOCOCCAL CONJUGATE VACCINE: A PHASE I CLINICAL TRIAL IN INFANTS 7 MONTH-OLD

10.26226/morressier.5731f0d7d462b8029237fd99 ◽

2016 ◽

Author(s):

Rinaldo Puga-Gomez

Keyword(s):

Clinical Trial ◽

Phase I ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Phase I Clinical Trial

Download Full-text

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718026292.793481389 ◽

2013 ◽

Author(s):

Steve Plaxe ◽

Kristy Ward

Keyword(s):

Ovarian Cancer ◽

Clinical Trial ◽

Phase I ◽

Recurrent Ovarian Cancer ◽

Phase I Clinical Trial ◽

Conditionally Replicative Adenovirus

Download Full-text

Faculty Opinions recommendation of GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726394953.793529283 ◽

2017 ◽

Author(s):

Lucy Dorrell

Keyword(s):

Clinical Trial ◽

Human Papillomavirus ◽

Phase I ◽

Therapeutic Vaccine ◽

Phase I Clinical Trial ◽

Cervical Cytology ◽

Human Papillomavirus 16 ◽

Normal Cervical Cytology

Download Full-text

Faculty Opinions recommendation of Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736011651.793576740 ◽

2020 ◽

Author(s):

Roger Barker

Keyword(s):

Clinical Trial ◽

Phase I ◽

Phase I Clinical Trial

Download Full-text

Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.474 ◽

2021 ◽

Vol 32 (1) ◽

pp. 120-121

Author(s):

S. Hiltbrunner ◽

C. Britschgi ◽

P. Schuberth ◽

L. Bankel ◽

T.D.L. Nguyen-Kim ◽

...

Keyword(s):

Clinical Trial ◽

T Cells ◽

Phase I ◽

Local Delivery ◽

Fibroblast Activation Protein ◽

Phase I Clinical Trial ◽

Pleural Mesothelioma ◽

First Report ◽

Car T Cells ◽

Car T

Download Full-text